Volume 25, Number 1—January 2019
CME ACTIVITY - Synopsis
Enterovirus A71 Infection and Neurologic Disease, Madrid, Spain, 2016
Table
Enterovirus serotype, localization of isolation, WHO clinical classification, and outcomes for 30 patients with enterovirus infection and neurologic disease, Madrid, 2016*
Patient no. | Patient age/sex | WHO clinical classification | Enterovirus source | Enterovirus serotype | Patient outcome |
---|---|---|---|---|---|
1 | 2 mo/M | Aseptic meningitis | CSF | Genotyped negative | Recovered |
2 | 16 d/F | Aseptic meningitis | CSF | ND | Recovered |
3 | 3 mo/F | Encephalitis | Nasopharyngeal aspirate | A71 | Recovered |
4 | 10 mo/F | Encephalitis | Nasopharyngeal aspirate | A71 | Recovered |
5 | 12 mo/M | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Unknown |
6 | 17 mo/F | Brainstem encephalitis | Nasopharyngeal aspirate | Genotyped negative | Unknown |
7 | 21 mo/F | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Cerebellar dysfunction |
8 | 22 mo/F | Encephalitis | Nasopharyngeal aspirate | Rhinovirus | Recovered |
9 | 19 mo/M | Encephalitis | Nasopharyngeal aspirate | A71 | Unknown |
10 | 18 mo/M | Encephalitis | Anal swab sample | A71 | Cerebellar dysfunction |
11 | 2 y/M | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Recovered |
12 | 2 y/M | Cardiopulmonary failure | Nasopharyngeal aspirate | A71 | Acquired brain damage |
13 | 23 mo/F | Cardiopulmonary failure | Anal swab sample | A71 | Cerebellar dysfunction |
14 | 2 y/M | Encephalitis | Nasopharyngeal aspirate | B | Recovered |
15 | 3 y/M | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Recovered |
16 | 3 y/F | Brainstem encephalitis | Anal swab sample | A71 | Recovered |
17 | 3 y/F | Cardiopulmonary failure | Nasopharyngeal aspirate | A71 | Paresis of the right upper limb |
18 | 4 y/F | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Cerebellar dysfunction |
19 | 4 y/M | Aseptic meningitis | CSF | ND | Recovered |
20 | 4 y/M | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Cerebellar dysfunction |
21 | 4 y/M | Aseptic meningitis | CSF | Echovirus | Recovered |
22 | 6 y/M | Aseptic meningitis | CSF | ND | Recovered |
23 | 6 y/F | Aseptic meningitis | CSF | Echovirus | Recovered |
24 | 7 y/M | Brainstem encephalitis | Nasopharyngeal aspirate | A71 | Cerebellar dysfunction |
25 | 1 mo/M | Encephalitis | CSF | A71 | Recovered |
26 | 4 y/M | Encephalitis | Nasopharyngeal aspirate | A71 | Recovered |
27 | 5 y/M | ANS dysfunction | Nasopharyngeal aspirate | A71 | Cerebellar dysfunction |
28 | 2 y/F | Encephalitis | Nasopharyngeal aspirate | A71 | Recovered |
29 | 2 y/M | Brainstem encephalitis | Anal swab sample | A71 | Recovered |
30 | 20 mo/M | Brainstem encephalitis | Anal swab sample | A71 | Peripheral facial paralysis |
*ANS, autonomic nervous system; CSF, cerebrospinal fluid; ND, not done; WHO, World Health Organization.
1These authors contributed equally to this article.